HSBC Holdings
LGND icon

HSBC Holdings’s Ligand Pharmaceuticals LGND Stock Holding History

HSBC Holdings’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3,527
Closed -$219K – 3127
2019
Q3 		$219K Hold
3,527
– – ﹤0.01% 2817
2019
Q2 		$251K Buy
+3,527
New +$260K ﹤0.01% 2427

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

HSBC Holdings's LGND Position: Q1 2026 in Review

HSBC Holdings opened a new position in Ligand Pharmaceuticals (LGND) in Q1 2026: 3,455 shares worth $690K. The stake represents ﹤0.01% of the portfolio and ranks #2057 among its holdings. This is a return to the name: HSBC Holdings previously reported a position in LGND as recently as Q4 2024.

HSBC Holdings first reported a position in LGND in Q3 2014 and has held it in 36 quarters since. The position peaked at $7.87M in Q1 2019. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • HSBC Holdings held 3,455 shares of Ligand Pharmaceuticals worth $690K as of Q1 2026.
  • Ligand Pharmaceuticals was a new HSBC Holdings position in Q1 2026.
  • Ligand Pharmaceuticals made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2057 holding.
  • HSBC Holdings first reported a position in Ligand Pharmaceuticals in Q3 2014 and has held it in 36 quarters since.
  • HSBC Holdings's Ligand Pharmaceuticals position peaked at $7.87M in Q1 2019.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.